Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Ascendis Pharma ADR (ASND)

Ascendis Pharma ADR (ASND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Ascendis Pharma ADR TUBORG BOULEVARD 12 HELLERUP G7 2900 DNK

www.ascendispharma.com Employees: 879 P: 45-7022-2244

Description:

Ascendis Pharma A/S is a biopharmaceutical company. The company's product pipeline consist of TransCon Human Growth Hormone, TransCon Treprostinil, TransCon Insulin, TransCon Peptide and TransCon Ranibizumab, which are in different clinical stage, for the treatments of hormone deficiency, endocrinology, central nervous system disorders, infectious diseases and diabetes. Its technology includes TransCon which develop prodrug therapies. Ascendis Pharma A/S is based in Denmark.

Key Statistics

Overview:

Market Capitalization, $K 7,542,651
Enterprise Value, $K 7,708,571
Shares Outstanding, K 60,642
Annual Sales, $ 288,670 K
Annual Net Income, $ -521,070 K
Last Quarter Sales, $ 63,590 K
Last Quarter Net Income, $ -109,080 K
EBIT, $ -342,180 K
EBITDA, $ -321,710 K
60-Month Beta 0.66
% of Insider Shareholders 40.00%
Float, K 36,385
% Float 60.00%
Short Volume Ratio 0.27

Growth:

1-Year Return 32.26%
3-Year Return -13.52%
5-Year Return 7.99%
5-Year Revenue Growth 2,209.36%
5-Year Earnings Growth -147.06%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -1.89 on 11/14/24
Next Earnings Date N/A
Earnings Per Share ttm -8.08
EPS Growth vs. Prev Qtr 7.80%
EPS Growth vs. Prev Year 39.42%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

ASND Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -48.77%
Profit Margin % -180.51%
Debt/Equity -9.83
Price/Sales 26.20
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -1.76
Interest Coverage -9.76
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar